Stocks Health care INMB
NASDAQ · Health careInmune Bio, Inc. (INMB)
It posted a net loss of $18.4M. In fiscal 2025 capital spending exceeded operating cash flow by $23.6M. At June 30, 2026 it held $18.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Inmune Bio, Inc. does
Inmune Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INMB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $50K | -$45.9M | -$1.86 | -$23.6M |
| 2024 | $14K | -$42.1M | -$2.11 | n/a |
| 2023 | $155K | -$30M | -$1.67 | n/a |
| 2022 | $374K | -$27.3M | -$1.52 | n/a |
| 2021 | $181K | -$30.3M | -$1.88 | n/a |
| 2020 | $11K | -$12.1M | -$1.01 | n/a |
Latest SEC filings
What Inmune Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- July 31, 2026Other event 8-K
- July 1, 2026
- June 23, 2026Other event 8-K
- June 17, 2026
- June 2, 2026Other event 8-K
- May 14, 2026Other event 8-K
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 5, 2026
Questions about INMB
What does Inmune Bio, Inc. do?
Inmune Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INMB.
Is Inmune Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.4M.
When did Inmune Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 23, 2026.
Similar companies
Follow INMB
Get an email when Inmune Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INMB: get an email when it filesWhere the numbers come from
Financial figures are the values Inmune Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.